|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin 64. 9–29, 2014. Erratum in. CA
Cancer J Clin. 64:3642014. View Article : Google Scholar
|
|
2
|
Zhang Y, Liu Z, Yu X, Zhang X, Lü S, Chen
X and Lü B: The association between metabolic abnormality and
endometrial cancer: A large case-control study in China. Gynecol
Oncol. 117:41–46. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Diabetes Association, . Executive
summary: Standards of medical care in diabetes-2014. Diabetes Care.
37:(Suppl 1). S5–S13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Febbraro T, Lengyel E and Romero IL: Old
drug, new trick: Repurposing metformin for gynecologic cancers?
Gynecol Oncol. 135:614–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stine JE and Bae-Jump V: Metformin and
gynecologic cancers. Obstet Gynecol Surv. 69:477–489. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan BK, Adya R, Chen J, Lehnert H, Cassia
LJ Sant and Randeva HS: Metformin treatment exerts antiinvasive and
antimetastatic effects in human endometrial carcinoma cells. J Clin
Endocrinol Metab. 96:808–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cantrell LA, Zhou C, Mendivil A, Malloy
KM, Gehrig PA and Bae-Jump VL: Metformin is a potent inhibitor of
endometrial cancer cell proliferation-implications for a novel
treatment strategy. Gynecol Oncol. 116:92–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko EM, Walter P, Jackson A, Clark L,
Franasiak J, Bolac C, Havrilesky LJ, Secord AA, Moore DT, Gehrig
PA, et al: Metformin is associated with improved survival in
endometrial cancer. Gynecol Oncol. 132:438–442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Riedmaier A Emami, Fisel P, Nies AT,
Schaeffeler E and Schwab M: Metformin and cancer: From the old
medicine cabinet to pharmacological pitfalls and prospects. Trends
Pharmacol Sci. 34:126–135. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsuji K, Kisu I, Banno K, Yanokura M, Ueki
A, Masuda K, Kobayashi Y, Yamagami W, Nomura H, Susumu N, et al:
Metformin: A possible drug for treatment of endometrial cancer.
Open J Obstet Gynecol. 2:1–6. 2012. View Article : Google Scholar
|
|
12
|
Al Hilli MM, Bakkum-Gamez JN, Mariani A,
Cliby WA, Mc Gree ME, Weaver AL, Dowdy SC and Podratz KC: The
effect of diabetes and metformin on clinical outcomes is negligible
in risk-adjusted endometrial cancer cohorts. Gynecol Oncol.
140:270–276. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ezewuiro O, Grushko TA, Kocherginsky M,
Habis M, Hurteau JA, Mills KA, Hunn J, Olopade OI, Fleming GF and
Romero IL: Association of Metformin Use with Outcomes in Advanced
Endometrial Cancer Treated with Chemotherapy. PLoS One.
11:e01471452016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitsuhashi A, Kiyokawa T, Sato Y and Shozu
M: Effects of metformin on endometrial cancer cell growth in vivo:
A preoperative prospective trial. Cancer. 120:2986–2995. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Indraccolo S, Randon G, Zulato E, Nardin
M, Aliberti C, Pomerri F, Casarin A and Nicoletto MO: Metformin: A
modulator of bevacizumab activity in cancer? A case report. Cancer
Biol Ther. 16:210–214. 2015. View Article : Google Scholar : PubMed/NCBI
|
